{"gene":"SYK","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1995,"finding":"Syk tandem SH2 domains bind dual phosphotyrosine sites in ITAM motifs of receptor signaling chains (e.g., immunoglobulin α and β chains of the BCR), leading to Syk activation. Homozygous syk-/- mice showed severe hemorrhaging and perinatal lethality, and syk mutation impaired pre-B cell differentiation by disrupting pre-BCR signaling.","method":"Gene targeting (knockout mouse), biochemical binding studies, lymphocyte development analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic and biochemical evidence, replicated across multiple studies, foundational knockout paper","pmids":["7477353"],"is_preprint":false},{"year":2001,"finding":"Syk is recruited and activated by direct binding to the integrin β3 cytoplasmic tail through its tandem SH2 domains in a phosphotyrosine-independent manner. Deletion of four C-terminal residues of the β3 tail decreased Syk binding and disrupted its physical association with integrin αIIbβ3, and cells expressing this mutant failed to show Syk activation or lamellipodia formation upon fibrinogen adhesion.","method":"Co-immunoprecipitation, pulldown assays, deletion mutagenesis, cell adhesion assays","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays plus functional mutagenesis with lamellipodia readout, single lab but multiple orthogonal methods","pmids":["11719224"],"is_preprint":false},{"year":2001,"finding":"BLNK mediates Syk-dependent Btk activation. In a reconstitution cell system, coexpression of BLNK allows Syk to phosphorylate Btk on tyrosine 551, enhancing Btk activity. This depends on interaction of Btk and BLNK via the Btk-SH2 domain. BCR-induced Btk phosphorylation and activation are significantly reduced in both BLNK-deficient and Syk-deficient B cells.","method":"Reconstitution cell system, phosphorylation assays, genetic deficiency models (BLNK-/- and Syk-/- B cells)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution system plus genetic validation in deficient B cells, multiple orthogonal methods","pmids":["11226282"],"is_preprint":false},{"year":1996,"finding":"Clustered Syk kinase domains are sufficient to autonomously trigger phagocytosis and filamentous actin redistribution in COS cells when expressed as chimeric transmembrane proteins. A point mutation in the Syk catalytic domain abolishes this response, and the kinase domain alone is sufficient for cytoskeletal coupling.","method":"Chimeric transmembrane protein expression, catalytic domain point mutagenesis, phagocytosis assay, actin redistribution assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — catalytic mutagenesis plus reconstitution in non-hematopoietic cells, directly establishes kinase-dependent mechanism","pmids":["8577722"],"is_preprint":false},{"year":2008,"finding":"SLP-65 is not only a Syk substrate but also a direct binding partner and activator of Syk. The SH2 domain of SLP-65 binds to an autophosphorylated tyrosine of Syk, creating a positive feedback loop. B cells unable to form the Syk/SLP-65 complex are defective in BCR-induced ERK, NF-κB, and NFAT (but not Akt) activation, are blocked in B-cell development, and show impaired sustained Ca2+ responses.","method":"Co-immunoprecipitation, B cell development analysis in mutant mice, calcium flux assays, signaling pathway analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, genetic mouse model, multiple functional readouts (Ca2+, ERK, NF-κB, development)","pmids":["18369315"],"is_preprint":false},{"year":2010,"finding":"CLEC-2 activates Syk through dimerization: the single YxxL-containing CLEC-2 cytoplasmic tail, when phosphorylated, activates Syk by cross-linking through Syk tandem SH2 domains at a 2:1 (CLEC-2:Syk) stoichiometry. CLEC-2 exists as a dimer in resting platelets and forms larger complexes upon activation.","method":"Peptide pull-down, surface plasmon resonance, quantitative Western blotting, tryptophan fluorescence, cross-linking, electron microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple biophysical and biochemical methods in one study, stoichiometry established rigorously","pmids":["20154219"],"is_preprint":false},{"year":2019,"finding":"Syk activation requires ppITAM binding to prime SYK for rapid LYN-mediated phosphorylation of Tyr-352, then Tyr-348 of the SH2-kinase linker, which facilitates activation loop phosphorylation and full SYK activation. ppITAM peptide alone strongly activates dimerized (GST-tagged) SYK but poorly activates monomeric unphosphorylated SYK; LYN alone activates monomeric SYK more than ppITAM does, and both together achieve rapid full activation.","method":"In vitro kinase assays with purified proteins (monomeric vs. obligatory dimeric SYK), immunoblot, phosphoproteomics (mass spectrometry), site-specific phosphorylation kinetics","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with multiple SYK forms, phosphoproteomic site identification, multiple orthogonal methods in single rigorous study","pmids":["30923129"],"is_preprint":false},{"year":2006,"finding":"Syk is required for pathogen engulfment in complement-mediated phagocytosis. Syk becomes tyrosine-phosphorylated and accumulates around nascent phagosomes upon C3bi-opsonized zymosan binding to CR3. Syk-siRNA or dominant-negative Syk impairs phagocytic engulfment. Syk regulates actin dynamics (accumulation and depolymerization) and RhoA activation with tyrosine phosphorylation of Vav during this process.","method":"siRNA knockdown, dominant-negative expression, phagocytosis quenching assay, immunofluorescence, RhoA activation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two loss-of-function approaches (siRNA + dominant-negative), multiple pathway readouts (actin, RhoA, Vav phosphorylation)","pmids":["16449524"],"is_preprint":false},{"year":2008,"finding":"Syk kinase is required for Dectin-1/Syk pathway collaboration with TLR/MyD88 pathways to induce optimal cytokine responses. Deficiency of Syk abolishes collaborative TNF, MIP-1α, and MIP-2 production and sustained IκB degradation/NF-κB nuclear translocation induced by co-stimulation of Dectin-1 with TLR2, 4, 5, 7, or 9.","method":"Syk-deficient macrophages, MyD88-deficient macrophages, cytokine measurement (ELISA), NF-κB nuclear translocation, IκB degradation assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deficiency models, multiple TLR partners tested, multiple downstream readouts, replicated with two deficient lines","pmids":["18200499"],"is_preprint":false},{"year":2003,"finding":"Syk phosphorylates PKCβI at Tyr-662 and PKCα at Tyr-658 in the membrane compartment of FcεRI-stimulated mast cells, dependent on prior PKC autophosphorylation of adjacent serine residues. These phosphorylations generate a binding site for the Grb-2 SH2 domain, recruiting Grb-2/Sos to the plasma membrane to activate the Ras/ERK pathway.","method":"In vitro kinase assay, mutagenesis of phosphorylation sites, SH2 domain binding assay, Ras/ERK activation assay in mast cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, functional pathway reconstitution in mast cells, multiple orthogonal methods","pmids":["12881490"],"is_preprint":false},{"year":2000,"finding":"Syk phosphorylates α-tubulin on tyrosine both in vitro and in intact B-lymphocytes. Following BCR engagement or pervanadate treatment, α-tubulin within the polymerized microtubule network is phosphorylated in a Syk-dependent manner. At low pervanadate concentrations, centrosomes show preferential tyrosine phosphorylation. Tyrosine-phosphorylated tubulin assembles into microtubules in vitro.","method":"In vitro kinase assay, immunofluorescence, Western blotting with anti-phosphotyrosine antibodies, Syk-deficient cell comparison","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay confirmed in Syk-expressing vs Syk-deficient cells, but functional consequence of tubulin phosphorylation not fully established","pmids":["10862713"],"is_preprint":false},{"year":2005,"finding":"Syk colocalizes with and copurifies with centrosomal component γ-tubulin, exhibits catalytic activity within centrosomes, and its centrosomal localization depends on intact kinase activity. Centrosomal Syk is degraded via ubiquitination and proteasomal degradation during mitosis. Unrestrained Syk overexpression causes multipolar mitotic spindles, supernumerary centrosomes, and cell death resembling mitotic catastrophe.","method":"Co-purification/colocalization with γ-tubulin, fluorescent protein chimera expression (DsRed-Syk), kinase-dead mutant analysis, mitotic analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-purification with centrosomal marker, kinase-dependent localization, functional overexpression phenotype, single lab","pmids":["16322234"],"is_preprint":false},{"year":2006,"finding":"Syk shuttles between nucleus and cytoplasm via an unconventional shuttling sequence near the junction of the catalytic domain and the linker B region. BCR engagement causes nuclear exclusion of Syk via protein kinase C activation and new protein synthesis. Nuclear Syk restricts stress-induced caspase 3 activation, while nuclear exclusion potentiates it.","method":"Deletion mutant analysis, subcellular fractionation, caspase 3 activation assay, PKC inhibition","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion mutants identify shuttling sequence, functional consequence (caspase 3) linked to localization, single lab","pmids":["16611990"],"is_preprint":false},{"year":1997,"finding":"Pyk2 tyrosine phosphorylation and activation following FcεRI aggregation in mast cells is downstream of Syk, not Src-family kinases. FcεRI-induced Pyk2 activation was dependent on Syk, whereas Pyk2 activation by G-protein-coupled receptors was Syk-independent.","method":"Genetic epistasis using Syk-deficient cells, pharmacological inhibition, immunoprecipitation/kinase assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established in Syk-deficient cells with pathway position defined, single lab","pmids":["9405454"],"is_preprint":false},{"year":2002,"finding":"In NK92 cells, Syk acts upstream of PI3K and signals through PI3K→Rac1→PAK1→MEK→ERK cascade for NK cytotoxicity. DAP12 tyrosine phosphorylation recruits and activates Syk upon tumor cell ligation. Kinase-deficient Syk or piceatannol blocked PI3K, Rac1, PAK1, MEK, ERK activation, perforin movement, and cytotoxicity. Constitutively active PI3K rescued downstream events in Syk-impaired NK cells.","method":"Dominant-negative/kinase-dead Syk, pharmacological inhibition (piceatannol), co-immunoprecipitation, constitutively active PI3K epistasis, cytotoxicity assay","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological loss-of-function with PI3K epistasis rescue, multiple pathway readouts, single lab","pmids":["11907067"],"is_preprint":false},{"year":2014,"finding":"Syk directly binds to and transactivates FLT3 in AML. Highly activated SYK is predominantly found in FLT3-ITD-positive AML and cooperates with FLT3-ITD to activate MYC transcriptional programs. SYK overexpression promotes resistance to FLT3-ITD-targeted therapy.","method":"Kinase activity profiling, co-immunoprecipitation (direct binding), in vivo FLT3-ITD mouse model, shRNA knockdown","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding shown by Co-IP, in vivo model, functional kinase assay, single lab","pmids":["24525236"],"is_preprint":false},{"year":2010,"finding":"In B cell activation, Syk opens BCR dimers by an inside-out signaling mechanism that amplifies BCR signaling, as demonstrated by high-resolution proximity ligation assay monitoring BCR conformation at 10-20 nm resolution.","method":"Proximity ligation assay (PLA) at nanoscale resolution, B cell activation assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel high-resolution method (PLA) directly demonstrating inside-out signaling, single lab, single method type","pmids":["24963139"],"is_preprint":false},{"year":2001,"finding":"Syk directly binds to the erythropoietin receptor (EpoR) through its tandem SH2 domains following Epo stimulation, with both N- and C-terminal SH2 domains contributing (C-terminal predominantly). This interaction only occurs after Epo activation (EpoR phosphorylation on tyrosine). Syk kinase activity is increased upon EpoR binding.","method":"Co-immunoprecipitation, far Western blotting with recombinant SH2 domain constructs, kinase activity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding shown by far Western and Co-IP with domain mapping, kinase activity confirmed, single lab","pmids":["9852052"],"is_preprint":false},{"year":2005,"finding":"Syk is required for TPL2 (Tpl2/Cot) activation downstream of TNF-α signaling. TNF-α-induced ERK activation through TPL2 depends on Syk tyrosine kinase activity. RIP1 and TRAF2 are required for TPL2-ERK engagement but are insufficient without Syk.","method":"Genetic epistasis (Syk-deficient cells), biochemical evidence (Co-IP), overexpression studies","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and biochemical epistasis, pathway position defined, single lab","pmids":["16291755"],"is_preprint":false},{"year":2021,"finding":"TRIM31 E3 ligase interacts with SYK and catalyzes K27-linked polyubiquitination at Lys375 and Lys517 of SYK. This K27-linked polyubiquitination promotes SYK plasma membrane translocation, binding to C-type lectin receptors, and prevents SHP-1 phosphatase interaction. TRIM31 deficiency in BMDCs and BMDMs dampens SYK-mediated signaling against C. albicans.","method":"Co-immunoprecipitation, ubiquitination assay (K27-linkage specific), mutagenesis (Lys375/517), membrane fractionation, TRIM31-/- mice","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-specific ubiquitination mutagenesis, membrane localization consequence, genetic mouse model validation, multiple methods in single study","pmids":["34362877"],"is_preprint":false},{"year":2020,"finding":"USP10 is a major deubiquitinase required for stabilization of SYK. Inhibition of USP10 leads to proteasome-mediated degradation of SYK. USP10 inhibition causes death of cells driven by active SYK or oncogenic FLT3 and potentiates anti-leukemic effects of FLT3 inhibition.","method":"USP10 inhibitor treatment, SYK protein level analysis, co-targeting experiments in AML cells","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and functional evidence for USP10-SYK relationship, single lab, mechanism inferred from inhibitor studies without direct DUB-substrate reconstitution described in abstract","pmids":["32015510"],"is_preprint":false},{"year":2020,"finding":"Cbl-mediated Syk degradation restrains plasma cell formation in germinal centers and promotes B cell light zone to dark zone transition. This degradation machinery attenuates BCR signaling by mitigating Kras/Erk and PI3K/Foxo1 pathways and restricting expression of plasma cell transcription factors in GC B cells.","method":"Mouse model defective in Cbl-mediated Syk degradation, signaling pathway analysis, transcription factor expression, flow cytometry","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model, multiple pathway readouts, single lab, mechanism linked to Cbl E3 ligase activity on Syk","pmids":["31873727"],"is_preprint":false},{"year":2014,"finding":"Syk binds to nucleolin and phosphorylates it on tyrosine, enhancing nucleolin's ability to bind Bcl-xL mRNA and stabilize it, thereby protecting cells from apoptosis induced by oxidative or genotoxic stress.","method":"Co-immunoprecipitation, in vitro kinase assay, mRNA stability assay, RNA interference (nucleolin knockdown), apoptosis assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and phosphorylation demonstrated, functional RNAi knockdown with apoptosis readout, single lab","pmids":["25092868"],"is_preprint":false},{"year":2015,"finding":"Syk is recruited to stress granules in a phosphorylation-dependent manner. Grb7 is a Syk-binding protein involved in recruiting Syk to stress granules. Syk recruitment promotes autophagosome formation and clearance of stress granules, enhancing cell survival after stress.","method":"Stress granule formation assay, Co-immunoprecipitation (Syk-Grb7), autophagosome formation assay, Syk inhibition/knockdown","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies Grb7 as recruitment factor, phosphorylation requirement established, functional autophagy readout, single lab","pmids":["26429917"],"is_preprint":false},{"year":2010,"finding":"Conserved C-terminal tyrosines Tyr-623, Tyr-624, and Tyr-625 of Syk regulate its kinase activity and ITAM binding. Mutation of all three to Phe results in increased autophosphorylation in resting cells, reduced binding to phosphorylated ITAM, reduced kinase activity toward exogenous substrate, and decreased FcεRI-induced degranulation and downstream signaling. Tyr-624 and especially Tyr-625 have major roles.","method":"Site-directed mutagenesis, in vitro kinase assay, ITAM binding assay, degranulation assay, downstream signaling analysis in Syk-deficient mast cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-specific mutagenesis with in vitro kinase assay and functional reconstitution in deficient mast cells, multiple orthogonal methods","pmids":["20554527"],"is_preprint":false},{"year":2017,"finding":"Syk is essential for γδTCR signal transduction and development of IL-17-producing γδT (γδT17) cells in the mouse thymus. Syk induces PI3K/Akt pathway activation upon γδTCR stimulation. ZAP70 cannot functionally substitute for Syk in γδT17 development. RhoH (adaptor that recruits Syk) deficiency ameliorates γδT17-dependent skin inflammation.","method":"Genetic mouse models (Syk conditional KO, RhoH KO, PI3K signaling-deficient mice), thymic development analysis, cytokine analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mouse models, pathway specificity (Syk vs ZAP70 non-substitutability), PI3K epistasis, in vivo inflammatory model","pmids":["29202478"],"is_preprint":false},{"year":2022,"finding":"SYK-deficient microglia cannot encase Aβ plaques, accelerating brain pathology and behavioral deficits. SYK deficiency impairs the PI3K-AKT-GSK-3β-mTOR pathway, incapacitating anabolic support required for disease-associated microglia (DAM) profile. However, SYK-deficient microglia can still proliferate and advance to an Apoe-expressing prodromal DAM stage via the DAP10 adapter pathway. The human TREM2R47H variant associated with high AD risk fails to activate SYK.","method":"Conditional SYK knockout in microglia, 5xFAD mouse model, Aβ plaque encasement assay, PI3K-AKT pathway analysis, DAM transcriptional profiling, TREM2R47H knock-in mice","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo, pathway analysis, DAP10 vs SYK epistasis, human variant validation, multiple readouts","pmids":["36306735"],"is_preprint":false},{"year":2019,"finding":"SYK inhibition blocks autophagic Tau degradation by acting upstream of the mTOR pathway. Pharmacological inhibition or knockdown of SYK decreases mTOR pathway activation and increases autophagic Tau degradation. In a tauopathy mouse model, chronic SYK inhibition reduced Tau accumulation, neuroinflammation, neuronal and synaptic loss, and reversed defective autophagy.","method":"SYK pharmacological inhibition, shRNA knockdown, mTOR pathway analysis, autophagic flux measurement, tauopathy mouse model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two loss-of-function approaches, mTOR pathway epistasis, in vivo validation, single lab","pmids":["31324720"],"is_preprint":false},{"year":2014,"finding":"SYK inhibition decreases Aβ production and increases Aβ clearance across the blood-brain barrier. SYK inhibition induces increased phosphorylation of inhibitory Ser-9 of GSK-3β by activating protein kinase A, providing a mechanism for reduction of Tau phosphorylation at GSK3β-dependent epitopes.","method":"Pharmacological SYK inhibition, SYK siRNA knockdown, transgenic mouse models (Aβ overexpression, P301S Tau), BBB clearance assay, GSK-3β Ser-9 phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition, mechanistic link to PKA-GSK3β-Tau axis, in vivo mouse model, single lab","pmids":["25331948"],"is_preprint":false},{"year":2021,"finding":"When ZAP70 is aberrantly expressed in B cells, it competes with SYK at the BCR signalosome and redirects SYK from NFAT-dependent negative selection signaling to tonic PI3K signaling, promoting B cell survival and impairing elimination of autoreactive/premalignant clones.","method":"Conditional ZAP70 expression in B cells, genetic mouse models (B-ALL, B-CLL), BCR signaling pathway analysis (NFAT vs PI3K), negative selection assay, autoantibody measurement","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mouse models, pathway redirection mechanistically established (NFAT vs PI3K), autoimmune and malignancy phenotypes, single rigorous study","pmids":["33878293"],"is_preprint":false},{"year":2013,"finding":"SYK regulates mTOR and its upstream activator AKT in AML. Both small-molecule SYK inhibition and SYK-directed shRNA suppressed mTOR and downstream signaling effectors, as well as AKT. SYK inhibition showed heterogeneous effects on MAPK pathway (downregulating MEK/ERK in some cell lines, paradoxical increase in RAS-mutated AML).","method":"Small-molecule SYK inhibition, shRNA knockdown, phospho-protein analysis (mTOR, AKT, MEK, ERK), AML cell viability assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two loss-of-function approaches (inhibitor + shRNA), multiple pathway readouts, single lab","pmids":["23535559"],"is_preprint":false},{"year":2001,"finding":"CrkL binds to Syk through its SH2 and SH3 domains and co-precipitates kinase-active Syk. CrkL serves as a molecular adapter between WASP and Syk, with both SH2 and SH3 domains of CrkL involved in Syk binding. WASP, CrkL, Syk, and Hic-5 incorporate into platelet cytoskeleton after platelet aggregation.","method":"Co-immunoprecipitation, GST-fusion domain pulldown, in vitro kinase assay, platelet cytoskeleton fractionation","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and in vitro kinase confirmation, single lab","pmids":["11313252"],"is_preprint":false},{"year":2023,"finding":"Itaconate directly inhibits SYK kinase through alkylation at the Cys593 site, suppressing inflammation.","method":"Biochemical alkylation assay, SYK kinase activity assay, site-specific mutation (Cys593), pharmacological inhibition in macrophages and in vivo","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — site-specific alkylation identified, but single lab, limited mutagenesis detail in abstract","pmids":["37897551"],"is_preprint":false}],"current_model":"SYK is a cytoplasmic non-receptor tyrosine kinase that is activated by binding of its tandem SH2 domains to dual-phosphorylated ITAMs in immune receptor signaling chains (BCR, FcRs, DAP12, CLEC-2) and by integrin β3 cytoplasmic tail binding in a phosphotyrosine-independent manner; full activation requires both ppITAM-mediated priming and LYN-mediated phosphorylation of the SH2-kinase linker (Tyr-348/352) followed by activation loop phosphorylation; once active, SYK phosphorylates key substrates (BLNK, PKCβI, α-tubulin, nucleolin, Btk) and signals through PI3K-AKT-mTOR, Ras/ERK, NF-κB, and NFAT pathways; its activity is spatiotemporally regulated by proteasomal degradation (Cbl), K27-linked polyubiquitination (TRIM31) promoting membrane translocation, deubiquitination (USP10), nucleocytoplasmic shuttling via a linker-domain sequence, and centrosomal localization; SYK is essential for B cell development, phagocytosis, NK cytotoxicity, γδT17 differentiation, platelet activation, microglial Aβ clearance, and vascular integrity."},"narrative":{"mechanistic_narrative":"SYK is a cytoplasmic non-receptor tyrosine kinase that couples immunoreceptor and adhesion-receptor engagement to downstream activation of the actin cytoskeleton and the PI3K-AKT-mTOR, Ras/ERK, NF-κB, and NFAT signaling pathways [PMID:7477353, PMID:12881490, PMID:11907067]. It is recruited to and activated by its tandem SH2 domains engaging dual-phosphorylated ITAMs in receptor signaling chains (e.g., the BCR Igα/β chains), with full activation requiring ppITAM-mediated priming followed by LYN-catalyzed phosphorylation of the SH2-kinase linker tyrosines Tyr-348/Tyr-352 and activation-loop phosphorylation [PMID:7477353, PMID:30923129]; it can also be engaged in a phosphotyrosine-independent manner through the integrin β3 cytoplasmic tail and through dimerization of single-YxxL receptors such as CLEC-2 [PMID:11719224, PMID:20154219]. Its clustered kinase domain is sufficient to autonomously drive phagocytosis and F-actin remodeling, and SYK directs actin dynamics, RhoA, and Vav during complement-mediated engulfment [PMID:8577722, PMID:16449524]. Active SYK propagates signaling by phosphorylating and partnering with substrates including the adaptor BLNK/SLP-65, which forms a positive-feedback complex and relays signal to Btk, PKCβI to recruit Grb2/Sos for Ras/ERK activation, α-tubulin, and nucleolin to stabilize Bcl-xL mRNA and resist apoptosis [PMID:11226282, PMID:18369315, PMID:12881490, PMID:10862713, PMID:25092868]. SYK abundance and localization are tightly controlled by Cbl-mediated proteasomal degradation, TRIM31-catalyzed K27-linked polyubiquitination promoting membrane translocation, and USP10-mediated deubiquitinative stabilization [PMID:34362877, PMID:32015510, PMID:31873727]. At the organismal level SYK is essential for B-cell development and vascular integrity, NK cytotoxicity, fungal/Dectin-1 immunity, γδT17 differentiation, and microglial encasement of amyloid plaques, and its dysregulation contributes to FLT3-ITD AML and to tau/Aβ pathology through mTOR and GSK-3β control [PMID:7477353, PMID:18200499, PMID:11907067, PMID:24525236, PMID:29202478, PMID:36306735, PMID:31324720].","teleology":[{"year":1995,"claim":"Established that SYK is the obligate ITAM-coupled kinase linking immunoreceptors to lymphocyte development and that it is required for vascular integrity in vivo.","evidence":"Knockout mice plus biochemical ITAM-binding studies and pre-B cell development analysis","pmids":["7477353"],"confidence":"High","gaps":["Did not define the activation-loop/linker phosphorylation steps required for catalytic activation","Did not resolve which receptor partners account for the hemorrhagic phenotype"]},{"year":1996,"claim":"Showed that the SYK kinase domain itself, when clustered, is sufficient to trigger phagocytosis and actin remodeling, defining a catalytic, kinase-dependent coupling to the cytoskeleton.","evidence":"Chimeric transmembrane SYK constructs with catalytic point mutant in COS cells, phagocytosis and actin assays","pmids":["8577722"],"confidence":"High","gaps":["Did not identify the cytoskeletal substrates downstream of the kinase domain","Used a non-hematopoietic reconstitution system"]},{"year":2001,"claim":"Defined non-canonical, phosphotyrosine-independent recruitment of SYK to the integrin β3 tail and identified direct receptor partners (EpoR) and adaptors (CrkL/WASP) that diversify SYK signaling beyond classical ITAMs.","evidence":"Co-IP, far-Western/SH2 domain mapping, deletion mutagenesis, adhesion and cytoskeletal fractionation assays","pmids":["11719224","9852052","11313252"],"confidence":"Medium","gaps":["Structural basis of phosphotyrosine-independent β3 binding not resolved","Single-lab binding studies for several partners"]},{"year":2001,"claim":"Resolved how SYK transmits BCR signal to Btk, showing BLNK/SLP-65 acts as both substrate and bridging adaptor for Btk Tyr-551 phosphorylation.","evidence":"Reconstitution cell system plus BLNK- and SYK-deficient B cells","pmids":["11226282"],"confidence":"High","gaps":["Did not establish stoichiometry of the SYK/BLNK/Btk assembly"]},{"year":2003,"claim":"Identified a direct substrate-to-pathway link by which SYK phosphorylates PKCβI/α to recruit Grb2/Sos and activate Ras/ERK in mast cells.","evidence":"In vitro kinase assay, phosphosite mutagenesis, SH2-binding and Ras/ERK readouts","pmids":["12881490"],"confidence":"High","gaps":["Dependence on prior PKC serine autophosphorylation leaves ordering of the kinase cascade incompletely mapped"]},{"year":2006,"claim":"Demonstrated SYK requirement in complement (CR3)-mediated phagocytosis, linking it to RhoA and Vav-driven actin dynamics at the phagosome.","evidence":"siRNA and dominant-negative SYK, immunofluorescence, RhoA activation assays","pmids":["16449524"],"confidence":"High","gaps":["Did not define the direct SYK substrate controlling actin depolymerization"]},{"year":2008,"claim":"Placed SYK at the node integrating C-type lectin (Dectin-1) and TLR/MyD88 signals for optimal innate cytokine responses.","evidence":"SYK- and MyD88-deficient macrophages with cytokine and NF-κB readouts","pmids":["18200499"],"confidence":"High","gaps":["Molecular point of SYK–MyD88 pathway convergence not defined"]},{"year":2008,"claim":"Revealed a positive-feedback loop in which SLP-65 binds an autophosphorylated SYK tyrosine to amplify and sustain BCR-driven ERK/NF-κB/NFAT and Ca2+ signaling.","evidence":"Reciprocal Co-IP, mutant mice, calcium flux and pathway analysis","pmids":["18369315"],"confidence":"High","gaps":["Akt arm shown to be SLP-65-independent but the alternate route not mapped"]},{"year":2010,"claim":"Clarified activation mechanisms for non-ITAM receptors, showing CLEC-2 activates SYK via 2:1 cross-linking and that SYK can open BCR dimers by inside-out signaling to amplify receptor signaling.","evidence":"Biophysical stoichiometry (SPR, cross-linking, EM) and nanoscale proximity ligation assays","pmids":["20154219","24963139"],"confidence":"Medium","gaps":["Inside-out conformational mechanism shown by a single method/lab","How dimer cross-linking is regulated in vivo unresolved"]},{"year":2010,"claim":"Mapped intramolecular regulatory determinants, identifying C-terminal Tyr-623/624/625 that tune SYK kinase activity and ITAM binding.","evidence":"Site-directed mutagenesis with in vitro kinase, ITAM-binding, and degranulation assays in SYK-deficient mast cells","pmids":["20554527"],"confidence":"High","gaps":["Structural mechanism by which these tyrosines couple to the active site not resolved"]},{"year":2019,"claim":"Reconstituted the two-step activation logic of SYK: ppITAM priming enables rapid LYN-mediated linker phosphorylation (Tyr-352 then Tyr-348) and activation-loop phosphorylation for full activity.","evidence":"In vitro kinase assays with monomeric vs obligate-dimeric purified SYK plus phosphoproteomics","pmids":["30923129"],"confidence":"High","gaps":["Kinetics of in-cell coordination between LYN and ITAM engagement not fully captured"]},{"year":2021,"claim":"Defined ubiquitin-based control of SYK localization and stability: TRIM31 K27-linked polyubiquitination drives membrane translocation and CLR binding while blocking SHP-1, complementing Cbl-mediated degradation and USP10-mediated stabilization.","evidence":"Site-specific ubiquitination mutagenesis, membrane fractionation, TRIM31-/- mice; Cbl-degradation-defective mice; USP10 inhibitor studies","pmids":["34362877","31873727","32015510"],"confidence":"Medium","gaps":["USP10–SYK relationship inferred from inhibitor studies without direct DUB-substrate reconstitution","Interplay between competing ubiquitin marks not integrated"]},{"year":2017,"claim":"Showed SYK is non-redundantly required (ZAP70 cannot substitute) for γδTCR-driven PI3K/Akt signaling and γδT17 development.","evidence":"Conditional SYK, RhoH, and PI3K-mutant mice with thymic development and skin inflammation readouts","pmids":["29202478"],"confidence":"High","gaps":["Molecular basis for SYK-vs-ZAP70 functional non-equivalence not defined"]},{"year":2021,"claim":"Established that aberrant ZAP70 competes with SYK at the BCR signalosome to redirect signaling from NFAT-driven negative selection to tonic PI3K survival signaling, promoting malignant/autoreactive clone persistence.","evidence":"Conditional ZAP70 expression and B-ALL/B-CLL mouse models with NFAT-vs-PI3K pathway analysis","pmids":["33878293"],"confidence":"High","gaps":["Biochemical basis of differential pathway output between the two kinases not resolved"]},{"year":2022,"claim":"Defined SYK as the signaling hub for disease-associated microglia, required for PI3K-AKT-GSK-3β-mTOR anabolic support and Aβ plaque encasement, with the AD-risk TREM2 R47H variant failing to engage it.","evidence":"Microglial conditional SYK knockout in 5xFAD mice, DAM profiling, DAP10 epistasis, TREM2 R47H knock-in","pmids":["36306735"],"confidence":"High","gaps":["How SYK selectively enables DAM anabolic state vs DAP10-driven proliferation mechanistically unresolved"]},{"year":2023,"claim":"Identified a small-molecule/metabolite control point: itaconate alkylates SYK Cys593 to inhibit its kinase activity and dampen inflammation.","evidence":"Biochemical alkylation, kinase activity assay, Cys593 mutation, in vivo macrophage inhibition","pmids":["37897551"],"confidence":"Medium","gaps":["Single lab with limited mutagenesis detail","Structural consequence of Cys593 alkylation on the active site not shown"]},{"year":null,"claim":"How SYK's distinct signaling outputs (cytoskeletal, survival/mTOR, NF-κB/NFAT) are selected by receptor context, ubiquitin marks, and subcellular localization remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking activation mode to downstream pathway choice","Functional consequences of centrosomal/nuclear SYK pools incompletely defined","Structural basis of competing ubiquitin and phosphorylation marks unintegrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,3,6,9,10,22,24]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,6,9,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,9,19]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,8,14,25,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,14,30]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[5,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[19,20,21]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[23,27]}],"complexes":["BCR signalosome","platelet cytoskeleton (WASP/CrkL/Hic-5)"],"partners":["BLNK","LYN","BTK","CLEC-2","DAP12","CRKL","GRB7","TRIM31"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P43405","full_name":"Tyrosine-protein kinase SYK","aliases":["Spleen tyrosine kinase","p72-Syk"],"length_aa":635,"mass_kda":72.1,"function":"Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development (PubMed:12387735, PubMed:33782605). Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include DEPTOR, VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK (PubMed:12456653, PubMed:15388330, PubMed:34634301, PubMed:8657103). Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition (PubMed:12456653). Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR also plays a role in T-cell receptor signaling. Also plays a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade (By similarity). Required for the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770). Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils (By similarity). Also functions downstream of receptors mediating cell adhesion (PubMed:12387735). Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Also plays a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response (By similarity)","subcellular_location":"Cell membrane; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/P43405/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SYK","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SYK","total_profiled":1310},"omim":[{"mim_id":"620484","title":"THROMBOCYTOPENIA 10; THC10","url":"https://www.omim.org/entry/620484"},{"mim_id":"619622","title":"LYMPHOCYTE TRANSMEMBRANE ADAPTOR 1; LAX1","url":"https://www.omim.org/entry/619622"},{"mim_id":"619381","title":"IMMUNODEFICIENCY 82 WITH SYSTEMIC INFLAMMATION; IMD82","url":"https://www.omim.org/entry/619381"},{"mim_id":"619374","title":"IMMUNODEFICIENCY 81; IMD81","url":"https://www.omim.org/entry/619374"},{"mim_id":"618814","title":"KILLER CELL LECTIN-LIKE RECEPTOR F2; KLRF2","url":"https://www.omim.org/entry/618814"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":69.1},{"tissue":"parathyroid gland","ntpm":82.3}],"url":"https://www.proteinatlas.org/search/SYK"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P43405","domains":[{"cath_id":"3.30.505.10","chopping":"2-114","consensus_level":"high","plddt":89.7478,"start":2,"end":114},{"cath_id":"3.30.505.10","chopping":"120-257","consensus_level":"medium","plddt":90.8979,"start":120,"end":257},{"cath_id":"3.30.200.20","chopping":"337-448","consensus_level":"medium","plddt":89.6797,"start":337,"end":448},{"cath_id":"1.10.510.10","chopping":"455-524_533-632","consensus_level":"medium","plddt":93.5291,"start":455,"end":632}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43405","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43405-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43405-F1-predicted_aligned_error_v6.png","plddt_mean":84.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SYK","jax_strain_url":"https://www.jax.org/strain/search?query=SYK"},"sequence":{"accession":"P43405","fasta_url":"https://rest.uniprot.org/uniprotkb/P43405.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43405/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43405"}},"corpus_meta":[{"pmid":"20467426","id":"PMC_20467426","title":"The SYK tyrosine kinase: a crucial player in diverse biological functions.","date":"2010","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20467426","citation_count":1108,"is_preprint":false},{"pmid":"7477353","id":"PMC_7477353","title":"Syk tyrosine kinase required for mouse viability and B-cell development.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7477353","citation_count":536,"is_preprint":false},{"pmid":"36306735","id":"PMC_36306735","title":"TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.","date":"2022","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/36306735","citation_count":381,"is_preprint":false},{"pmid":"10689303","id":"PMC_10689303","title":"Tyrosine kinase SYK: essential functions for immunoreceptor signalling.","date":"2000","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/10689303","citation_count":324,"is_preprint":false},{"pmid":"18200499","id":"PMC_18200499","title":"Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18200499","citation_count":303,"is_preprint":false},{"pmid":"19913447","id":"PMC_19913447","title":"Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils.","date":"2009","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19913447","citation_count":249,"is_preprint":false},{"pmid":"11481033","id":"PMC_11481033","title":"Structure and function of Syk protein-tyrosine kinase.","date":"2001","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11481033","citation_count":241,"is_preprint":false},{"pmid":"36257314","id":"PMC_36257314","title":"SYK coordinates neuroprotective microglial responses in neurodegenerative disease.","date":"2022","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/36257314","citation_count":236,"is_preprint":false},{"pmid":"31324751","id":"PMC_31324751","title":"Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31324751","citation_count":219,"is_preprint":false},{"pmid":"20206686","id":"PMC_20206686","title":"The Src, Syk, and Tec family kinases: distinct types of molecular switches.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/20206686","citation_count":202,"is_preprint":false},{"pmid":"24975478","id":"PMC_24975478","title":"Getting Syk: spleen tyrosine kinase as a therapeutic target.","date":"2014","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24975478","citation_count":197,"is_preprint":false},{"pmid":"15797511","id":"PMC_15797511","title":"Src and Syk kinases: key regulators of phagocytic cell activation.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15797511","citation_count":173,"is_preprint":false},{"pmid":"11676469","id":"PMC_11676469","title":"Syk expression and novel function in a wide variety of tissues.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11676469","citation_count":151,"is_preprint":false},{"pmid":"25045209","id":"PMC_25045209","title":"Functional roles of Syk in macrophage-mediated inflammatory responses.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25045209","citation_count":149,"is_preprint":false},{"pmid":"28754125","id":"PMC_28754125","title":"Syk inhibitors in clinical development for hematological malignancies.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28754125","citation_count":140,"is_preprint":false},{"pmid":"19306898","id":"PMC_19306898","title":"Syk and pTyr'd: Signaling through the B cell antigen receptor.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19306898","citation_count":139,"is_preprint":false},{"pmid":"15212616","id":"PMC_15212616","title":"Targeting Syk as a treatment for allergic and autoimmune disorders.","date":"2004","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/15212616","citation_count":138,"is_preprint":false},{"pmid":"11719224","id":"PMC_11719224","title":"Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains.","date":"2001","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11719224","citation_count":131,"is_preprint":false},{"pmid":"21334257","id":"PMC_21334257","title":"Syk-coupled C-type lectins in immunity.","date":"2011","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21334257","citation_count":128,"is_preprint":false},{"pmid":"22776094","id":"PMC_22776094","title":"The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22776094","citation_count":127,"is_preprint":false},{"pmid":"24525236","id":"PMC_24525236","title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24525236","citation_count":127,"is_preprint":false},{"pmid":"12217388","id":"PMC_12217388","title":"Protein tyrosine kinase Syk in mast cell signaling.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12217388","citation_count":119,"is_preprint":false},{"pmid":"24963139","id":"PMC_24963139","title":"B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk.","date":"2014","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/24963139","citation_count":118,"is_preprint":false},{"pmid":"20154219","id":"PMC_20154219","title":"CLEC-2 activates Syk through dimerization.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20154219","citation_count":116,"is_preprint":false},{"pmid":"11226282","id":"PMC_11226282","title":"BLNK mediates Syk-dependent Btk activation.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226282","citation_count":115,"is_preprint":false},{"pmid":"18401419","id":"PMC_18401419","title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18401419","citation_count":115,"is_preprint":false},{"pmid":"25447675","id":"PMC_25447675","title":"Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25447675","citation_count":114,"is_preprint":false},{"pmid":"22186994","id":"PMC_22186994","title":"CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22186994","citation_count":113,"is_preprint":false},{"pmid":"31926564","id":"PMC_31926564","title":"Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31926564","citation_count":111,"is_preprint":false},{"pmid":"8577722","id":"PMC_8577722","title":"Clustered syk tyrosine kinase domains trigger phagocytosis.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8577722","citation_count":97,"is_preprint":false},{"pmid":"16442709","id":"PMC_16442709","title":"The Syk tyrosine kinase: a new negative regulator in tumor growth and progression.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16442709","citation_count":95,"is_preprint":false},{"pmid":"21552259","id":"PMC_21552259","title":"Alternative splicing of SYK regulates mitosis and cell survival.","date":"2011","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21552259","citation_count":95,"is_preprint":false},{"pmid":"11907067","id":"PMC_11907067","title":"Syk regulation of phosphoinositide 3-kinase-dependent NK cell function.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11907067","citation_count":93,"is_preprint":false},{"pmid":"10677523","id":"PMC_10677523","title":"Role of Syk in B-cell development and antigen-receptor signaling.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10677523","citation_count":92,"is_preprint":false},{"pmid":"29537660","id":"PMC_29537660","title":"Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.","date":"2018","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/29537660","citation_count":86,"is_preprint":false},{"pmid":"19909371","id":"PMC_19909371","title":"Autoinhibition and adapter function of Syk.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19909371","citation_count":77,"is_preprint":false},{"pmid":"35551173","id":"PMC_35551173","title":"Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35551173","citation_count":74,"is_preprint":false},{"pmid":"16449524","id":"PMC_16449524","title":"Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16449524","citation_count":72,"is_preprint":false},{"pmid":"27014261","id":"PMC_27014261","title":"Targeting Syk in Autoimmune Rheumatic Diseases.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27014261","citation_count":70,"is_preprint":false},{"pmid":"18369315","id":"PMC_18369315","title":"The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18369315","citation_count":69,"is_preprint":false},{"pmid":"36331249","id":"PMC_36331249","title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.","date":"2022","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/36331249","citation_count":68,"is_preprint":false},{"pmid":"19124456","id":"PMC_19124456","title":"Protein tyrosine kinase, syk: a key player in phagocytic cells.","date":"2009","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19124456","citation_count":67,"is_preprint":false},{"pmid":"29487599","id":"PMC_29487599","title":"Dectin-1-Syk-CARD9 Signaling Pathway in TB Immunity.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29487599","citation_count":63,"is_preprint":false},{"pmid":"25331948","id":"PMC_25331948","title":"The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25331948","citation_count":59,"is_preprint":false},{"pmid":"12881490","id":"PMC_12881490","title":"A Ras activation pathway dependent on Syk phosphorylation of protein kinase C.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12881490","citation_count":59,"is_preprint":false},{"pmid":"25388286","id":"PMC_25388286","title":"SYK is a candidate kinase target for the treatment of advanced prostate cancer.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25388286","citation_count":59,"is_preprint":false},{"pmid":"17669674","id":"PMC_17669674","title":"Syk inhibitors as treatment for allergic rhinitis.","date":"2007","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17669674","citation_count":58,"is_preprint":false},{"pmid":"16322234","id":"PMC_16322234","title":"The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16322234","citation_count":57,"is_preprint":false},{"pmid":"11675365","id":"PMC_11675365","title":"Syk expression in endothelial cells and their morphologic defects in embryonic Syk-deficient mice.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11675365","citation_count":57,"is_preprint":false},{"pmid":"10862713","id":"PMC_10862713","title":"Syk-dependent phosphorylation of microtubules in activated B-lymphocytes.","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10862713","citation_count":57,"is_preprint":false},{"pmid":"16611990","id":"PMC_16611990","title":"Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16611990","citation_count":55,"is_preprint":false},{"pmid":"16185147","id":"PMC_16185147","title":"Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.","date":"2005","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/16185147","citation_count":52,"is_preprint":false},{"pmid":"20236696","id":"PMC_20236696","title":"Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.","date":"2010","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20236696","citation_count":50,"is_preprint":false},{"pmid":"23535559","id":"PMC_23535559","title":"SYK regulates mTOR signaling in AML.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23535559","citation_count":49,"is_preprint":false},{"pmid":"26429917","id":"PMC_26429917","title":"Syk Is Recruited to Stress Granules and Promotes Their Clearance through Autophagy.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26429917","citation_count":48,"is_preprint":false},{"pmid":"29202478","id":"PMC_29202478","title":"γδTCR recruits the Syk/PI3K axis to drive proinflammatory differentiation program.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29202478","citation_count":48,"is_preprint":false},{"pmid":"21438742","id":"PMC_21438742","title":"The Syk kinase as a therapeutic target in leukemia and lymphoma.","date":"2011","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/21438742","citation_count":47,"is_preprint":false},{"pmid":"9405454","id":"PMC_9405454","title":"Activation of protein-tyrosine kinase Pyk2 is downstream of Syk in FcepsilonRI signaling.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9405454","citation_count":47,"is_preprint":false},{"pmid":"19670961","id":"PMC_19670961","title":"Therapeutic prospect of Syk inhibitors.","date":"2009","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/19670961","citation_count":46,"is_preprint":false},{"pmid":"38555386","id":"PMC_38555386","title":"PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38555386","citation_count":45,"is_preprint":false},{"pmid":"29401256","id":"PMC_29401256","title":"SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.","date":"2018","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29401256","citation_count":42,"is_preprint":false},{"pmid":"30282825","id":"PMC_30282825","title":"SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30282825","citation_count":41,"is_preprint":false},{"pmid":"24013589","id":"PMC_24013589","title":"Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24013589","citation_count":41,"is_preprint":false},{"pmid":"27356299","id":"PMC_27356299","title":"Cholesterol crystals activate Syk and PI3 kinase in human macrophages and dendritic cells.","date":"2016","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/27356299","citation_count":41,"is_preprint":false},{"pmid":"11313252","id":"PMC_11313252","title":"CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11313252","citation_count":40,"is_preprint":false},{"pmid":"16085052","id":"PMC_16085052","title":"Effector-induced Syk-mediated phosphorylation in human erythrocytes.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16085052","citation_count":40,"is_preprint":false},{"pmid":"30923129","id":"PMC_30923129","title":"A reevaluation of the spleen tyrosine kinase (SYK) activation mechanism.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30923129","citation_count":39,"is_preprint":false},{"pmid":"16754322","id":"PMC_16754322","title":"Complement-mediated phagocytosis--the role of Syk.","date":"2006","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/16754322","citation_count":39,"is_preprint":false},{"pmid":"29052597","id":"PMC_29052597","title":"SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/29052597","citation_count":36,"is_preprint":false},{"pmid":"21518255","id":"PMC_21518255","title":"TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21518255","citation_count":35,"is_preprint":false},{"pmid":"31974273","id":"PMC_31974273","title":"Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31974273","citation_count":35,"is_preprint":false},{"pmid":"11250739","id":"PMC_11250739","title":"Syk: a new player in the field of breast cancer.","date":"2000","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/11250739","citation_count":34,"is_preprint":false},{"pmid":"32379705","id":"PMC_32379705","title":"Identification of SYK inhibitor, R406 as a novel senolytic agent.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32379705","citation_count":34,"is_preprint":false},{"pmid":"31324720","id":"PMC_31324720","title":"Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31324720","citation_count":33,"is_preprint":false},{"pmid":"31771968","id":"PMC_31771968","title":"Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31771968","citation_count":33,"is_preprint":false},{"pmid":"29241811","id":"PMC_29241811","title":"Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29241811","citation_count":33,"is_preprint":false},{"pmid":"21074890","id":"PMC_21074890","title":"Syk mediates BCR- and CD40-signaling integration during B cell activation.","date":"2010","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21074890","citation_count":33,"is_preprint":false},{"pmid":"35130124","id":"PMC_35130124","title":"Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases.","date":"2022","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/35130124","citation_count":32,"is_preprint":false},{"pmid":"33727419","id":"PMC_33727419","title":"Diverse innate stimuli activate basophils through pathways involving Syk and IκB kinases.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33727419","citation_count":31,"is_preprint":false},{"pmid":"32015510","id":"PMC_32015510","title":"Inhibition of the deubiquitinase USP10 induces degradation of SYK.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32015510","citation_count":30,"is_preprint":false},{"pmid":"29611449","id":"PMC_29611449","title":"Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.","date":"2018","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29611449","citation_count":29,"is_preprint":false},{"pmid":"24523870","id":"PMC_24523870","title":"SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24523870","citation_count":29,"is_preprint":false},{"pmid":"33878293","id":"PMC_33878293","title":"Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33878293","citation_count":28,"is_preprint":false},{"pmid":"34362877","id":"PMC_34362877","title":"TRIM31 facilitates K27-linked polyubiquitination of SYK to regulate antifungal immunity.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34362877","citation_count":28,"is_preprint":false},{"pmid":"30742098","id":"PMC_30742098","title":"Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30742098","citation_count":28,"is_preprint":false},{"pmid":"21981270","id":"PMC_21981270","title":"Phosphorylated Syk expression is enhanced in Nasu-Hakola disease brains.","date":"2011","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/21981270","citation_count":26,"is_preprint":false},{"pmid":"26051661","id":"PMC_26051661","title":"A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.","date":"2015","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/26051661","citation_count":25,"is_preprint":false},{"pmid":"20554527","id":"PMC_20554527","title":"Tyrosines in the carboxyl terminus regulate Syk kinase activity and function.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20554527","citation_count":25,"is_preprint":false},{"pmid":"26018734","id":"PMC_26018734","title":"CD59 signaling and membrane pores drive Syk-dependent erythrocyte necroptosis.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/26018734","citation_count":24,"is_preprint":false},{"pmid":"9852052","id":"PMC_9852052","title":"Physical and functional interaction between p72(syk) and erythropoietin receptor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9852052","citation_count":24,"is_preprint":false},{"pmid":"35398488","id":"PMC_35398488","title":"SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35398488","citation_count":23,"is_preprint":false},{"pmid":"15337524","id":"PMC_15337524","title":"Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells.","date":"2004","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/15337524","citation_count":22,"is_preprint":false},{"pmid":"26653844","id":"PMC_26653844","title":"Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.","date":"2015","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26653844","citation_count":21,"is_preprint":false},{"pmid":"33634985","id":"PMC_33634985","title":"CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33634985","citation_count":21,"is_preprint":false},{"pmid":"37897551","id":"PMC_37897551","title":"Itaconate inhibits SYK through alkylation and suppresses inflammation against hvKP induced intestinal dysbiosis.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37897551","citation_count":20,"is_preprint":false},{"pmid":"31873727","id":"PMC_31873727","title":"Syk degradation restrains plasma cell formation and promotes zonal transitions in germinal centers.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31873727","citation_count":20,"is_preprint":false},{"pmid":"25092868","id":"PMC_25092868","title":"Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25092868","citation_count":20,"is_preprint":false},{"pmid":"16291755","id":"PMC_16291755","title":"The tyrosine kinase Syk regulates TPL2 activation signals.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16291755","citation_count":20,"is_preprint":false},{"pmid":"23955076","id":"PMC_23955076","title":"Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23955076","citation_count":20,"is_preprint":false},{"pmid":"26148346","id":"PMC_26148346","title":"Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.","date":"2015","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/26148346","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43790,"output_tokens":8525,"usd":0.129623,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18384,"output_tokens":5215,"usd":0.111147,"stage2_stop_reason":"end_turn"},"total_usd":0.24077,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Syk tandem SH2 domains bind dual phosphotyrosine sites in ITAM motifs of receptor signaling chains (e.g., immunoglobulin α and β chains of the BCR), leading to Syk activation. Homozygous syk-/- mice showed severe hemorrhaging and perinatal lethality, and syk mutation impaired pre-B cell differentiation by disrupting pre-BCR signaling.\",\n      \"method\": \"Gene targeting (knockout mouse), biochemical binding studies, lymphocyte development analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic and biochemical evidence, replicated across multiple studies, foundational knockout paper\",\n      \"pmids\": [\"7477353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Syk is recruited and activated by direct binding to the integrin β3 cytoplasmic tail through its tandem SH2 domains in a phosphotyrosine-independent manner. Deletion of four C-terminal residues of the β3 tail decreased Syk binding and disrupted its physical association with integrin αIIbβ3, and cells expressing this mutant failed to show Syk activation or lamellipodia formation upon fibrinogen adhesion.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assays, deletion mutagenesis, cell adhesion assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays plus functional mutagenesis with lamellipodia readout, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"11719224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BLNK mediates Syk-dependent Btk activation. In a reconstitution cell system, coexpression of BLNK allows Syk to phosphorylate Btk on tyrosine 551, enhancing Btk activity. This depends on interaction of Btk and BLNK via the Btk-SH2 domain. BCR-induced Btk phosphorylation and activation are significantly reduced in both BLNK-deficient and Syk-deficient B cells.\",\n      \"method\": \"Reconstitution cell system, phosphorylation assays, genetic deficiency models (BLNK-/- and Syk-/- B cells)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution system plus genetic validation in deficient B cells, multiple orthogonal methods\",\n      \"pmids\": [\"11226282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Clustered Syk kinase domains are sufficient to autonomously trigger phagocytosis and filamentous actin redistribution in COS cells when expressed as chimeric transmembrane proteins. A point mutation in the Syk catalytic domain abolishes this response, and the kinase domain alone is sufficient for cytoskeletal coupling.\",\n      \"method\": \"Chimeric transmembrane protein expression, catalytic domain point mutagenesis, phagocytosis assay, actin redistribution assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — catalytic mutagenesis plus reconstitution in non-hematopoietic cells, directly establishes kinase-dependent mechanism\",\n      \"pmids\": [\"8577722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SLP-65 is not only a Syk substrate but also a direct binding partner and activator of Syk. The SH2 domain of SLP-65 binds to an autophosphorylated tyrosine of Syk, creating a positive feedback loop. B cells unable to form the Syk/SLP-65 complex are defective in BCR-induced ERK, NF-κB, and NFAT (but not Akt) activation, are blocked in B-cell development, and show impaired sustained Ca2+ responses.\",\n      \"method\": \"Co-immunoprecipitation, B cell development analysis in mutant mice, calcium flux assays, signaling pathway analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, genetic mouse model, multiple functional readouts (Ca2+, ERK, NF-κB, development)\",\n      \"pmids\": [\"18369315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLEC-2 activates Syk through dimerization: the single YxxL-containing CLEC-2 cytoplasmic tail, when phosphorylated, activates Syk by cross-linking through Syk tandem SH2 domains at a 2:1 (CLEC-2:Syk) stoichiometry. CLEC-2 exists as a dimer in resting platelets and forms larger complexes upon activation.\",\n      \"method\": \"Peptide pull-down, surface plasmon resonance, quantitative Western blotting, tryptophan fluorescence, cross-linking, electron microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple biophysical and biochemical methods in one study, stoichiometry established rigorously\",\n      \"pmids\": [\"20154219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Syk activation requires ppITAM binding to prime SYK for rapid LYN-mediated phosphorylation of Tyr-352, then Tyr-348 of the SH2-kinase linker, which facilitates activation loop phosphorylation and full SYK activation. ppITAM peptide alone strongly activates dimerized (GST-tagged) SYK but poorly activates monomeric unphosphorylated SYK; LYN alone activates monomeric SYK more than ppITAM does, and both together achieve rapid full activation.\",\n      \"method\": \"In vitro kinase assays with purified proteins (monomeric vs. obligatory dimeric SYK), immunoblot, phosphoproteomics (mass spectrometry), site-specific phosphorylation kinetics\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with multiple SYK forms, phosphoproteomic site identification, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"30923129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Syk is required for pathogen engulfment in complement-mediated phagocytosis. Syk becomes tyrosine-phosphorylated and accumulates around nascent phagosomes upon C3bi-opsonized zymosan binding to CR3. Syk-siRNA or dominant-negative Syk impairs phagocytic engulfment. Syk regulates actin dynamics (accumulation and depolymerization) and RhoA activation with tyrosine phosphorylation of Vav during this process.\",\n      \"method\": \"siRNA knockdown, dominant-negative expression, phagocytosis quenching assay, immunofluorescence, RhoA activation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two loss-of-function approaches (siRNA + dominant-negative), multiple pathway readouts (actin, RhoA, Vav phosphorylation)\",\n      \"pmids\": [\"16449524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Syk kinase is required for Dectin-1/Syk pathway collaboration with TLR/MyD88 pathways to induce optimal cytokine responses. Deficiency of Syk abolishes collaborative TNF, MIP-1α, and MIP-2 production and sustained IκB degradation/NF-κB nuclear translocation induced by co-stimulation of Dectin-1 with TLR2, 4, 5, 7, or 9.\",\n      \"method\": \"Syk-deficient macrophages, MyD88-deficient macrophages, cytokine measurement (ELISA), NF-κB nuclear translocation, IκB degradation assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deficiency models, multiple TLR partners tested, multiple downstream readouts, replicated with two deficient lines\",\n      \"pmids\": [\"18200499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Syk phosphorylates PKCβI at Tyr-662 and PKCα at Tyr-658 in the membrane compartment of FcεRI-stimulated mast cells, dependent on prior PKC autophosphorylation of adjacent serine residues. These phosphorylations generate a binding site for the Grb-2 SH2 domain, recruiting Grb-2/Sos to the plasma membrane to activate the Ras/ERK pathway.\",\n      \"method\": \"In vitro kinase assay, mutagenesis of phosphorylation sites, SH2 domain binding assay, Ras/ERK activation assay in mast cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, functional pathway reconstitution in mast cells, multiple orthogonal methods\",\n      \"pmids\": [\"12881490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Syk phosphorylates α-tubulin on tyrosine both in vitro and in intact B-lymphocytes. Following BCR engagement or pervanadate treatment, α-tubulin within the polymerized microtubule network is phosphorylated in a Syk-dependent manner. At low pervanadate concentrations, centrosomes show preferential tyrosine phosphorylation. Tyrosine-phosphorylated tubulin assembles into microtubules in vitro.\",\n      \"method\": \"In vitro kinase assay, immunofluorescence, Western blotting with anti-phosphotyrosine antibodies, Syk-deficient cell comparison\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay confirmed in Syk-expressing vs Syk-deficient cells, but functional consequence of tubulin phosphorylation not fully established\",\n      \"pmids\": [\"10862713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Syk colocalizes with and copurifies with centrosomal component γ-tubulin, exhibits catalytic activity within centrosomes, and its centrosomal localization depends on intact kinase activity. Centrosomal Syk is degraded via ubiquitination and proteasomal degradation during mitosis. Unrestrained Syk overexpression causes multipolar mitotic spindles, supernumerary centrosomes, and cell death resembling mitotic catastrophe.\",\n      \"method\": \"Co-purification/colocalization with γ-tubulin, fluorescent protein chimera expression (DsRed-Syk), kinase-dead mutant analysis, mitotic analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-purification with centrosomal marker, kinase-dependent localization, functional overexpression phenotype, single lab\",\n      \"pmids\": [\"16322234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Syk shuttles between nucleus and cytoplasm via an unconventional shuttling sequence near the junction of the catalytic domain and the linker B region. BCR engagement causes nuclear exclusion of Syk via protein kinase C activation and new protein synthesis. Nuclear Syk restricts stress-induced caspase 3 activation, while nuclear exclusion potentiates it.\",\n      \"method\": \"Deletion mutant analysis, subcellular fractionation, caspase 3 activation assay, PKC inhibition\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion mutants identify shuttling sequence, functional consequence (caspase 3) linked to localization, single lab\",\n      \"pmids\": [\"16611990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Pyk2 tyrosine phosphorylation and activation following FcεRI aggregation in mast cells is downstream of Syk, not Src-family kinases. FcεRI-induced Pyk2 activation was dependent on Syk, whereas Pyk2 activation by G-protein-coupled receptors was Syk-independent.\",\n      \"method\": \"Genetic epistasis using Syk-deficient cells, pharmacological inhibition, immunoprecipitation/kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established in Syk-deficient cells with pathway position defined, single lab\",\n      \"pmids\": [\"9405454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In NK92 cells, Syk acts upstream of PI3K and signals through PI3K→Rac1→PAK1→MEK→ERK cascade for NK cytotoxicity. DAP12 tyrosine phosphorylation recruits and activates Syk upon tumor cell ligation. Kinase-deficient Syk or piceatannol blocked PI3K, Rac1, PAK1, MEK, ERK activation, perforin movement, and cytotoxicity. Constitutively active PI3K rescued downstream events in Syk-impaired NK cells.\",\n      \"method\": \"Dominant-negative/kinase-dead Syk, pharmacological inhibition (piceatannol), co-immunoprecipitation, constitutively active PI3K epistasis, cytotoxicity assay\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological loss-of-function with PI3K epistasis rescue, multiple pathway readouts, single lab\",\n      \"pmids\": [\"11907067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Syk directly binds to and transactivates FLT3 in AML. Highly activated SYK is predominantly found in FLT3-ITD-positive AML and cooperates with FLT3-ITD to activate MYC transcriptional programs. SYK overexpression promotes resistance to FLT3-ITD-targeted therapy.\",\n      \"method\": \"Kinase activity profiling, co-immunoprecipitation (direct binding), in vivo FLT3-ITD mouse model, shRNA knockdown\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by Co-IP, in vivo model, functional kinase assay, single lab\",\n      \"pmids\": [\"24525236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In B cell activation, Syk opens BCR dimers by an inside-out signaling mechanism that amplifies BCR signaling, as demonstrated by high-resolution proximity ligation assay monitoring BCR conformation at 10-20 nm resolution.\",\n      \"method\": \"Proximity ligation assay (PLA) at nanoscale resolution, B cell activation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel high-resolution method (PLA) directly demonstrating inside-out signaling, single lab, single method type\",\n      \"pmids\": [\"24963139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Syk directly binds to the erythropoietin receptor (EpoR) through its tandem SH2 domains following Epo stimulation, with both N- and C-terminal SH2 domains contributing (C-terminal predominantly). This interaction only occurs after Epo activation (EpoR phosphorylation on tyrosine). Syk kinase activity is increased upon EpoR binding.\",\n      \"method\": \"Co-immunoprecipitation, far Western blotting with recombinant SH2 domain constructs, kinase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by far Western and Co-IP with domain mapping, kinase activity confirmed, single lab\",\n      \"pmids\": [\"9852052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Syk is required for TPL2 (Tpl2/Cot) activation downstream of TNF-α signaling. TNF-α-induced ERK activation through TPL2 depends on Syk tyrosine kinase activity. RIP1 and TRAF2 are required for TPL2-ERK engagement but are insufficient without Syk.\",\n      \"method\": \"Genetic epistasis (Syk-deficient cells), biochemical evidence (Co-IP), overexpression studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and biochemical epistasis, pathway position defined, single lab\",\n      \"pmids\": [\"16291755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM31 E3 ligase interacts with SYK and catalyzes K27-linked polyubiquitination at Lys375 and Lys517 of SYK. This K27-linked polyubiquitination promotes SYK plasma membrane translocation, binding to C-type lectin receptors, and prevents SHP-1 phosphatase interaction. TRIM31 deficiency in BMDCs and BMDMs dampens SYK-mediated signaling against C. albicans.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K27-linkage specific), mutagenesis (Lys375/517), membrane fractionation, TRIM31-/- mice\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific ubiquitination mutagenesis, membrane localization consequence, genetic mouse model validation, multiple methods in single study\",\n      \"pmids\": [\"34362877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"USP10 is a major deubiquitinase required for stabilization of SYK. Inhibition of USP10 leads to proteasome-mediated degradation of SYK. USP10 inhibition causes death of cells driven by active SYK or oncogenic FLT3 and potentiates anti-leukemic effects of FLT3 inhibition.\",\n      \"method\": \"USP10 inhibitor treatment, SYK protein level analysis, co-targeting experiments in AML cells\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and functional evidence for USP10-SYK relationship, single lab, mechanism inferred from inhibitor studies without direct DUB-substrate reconstitution described in abstract\",\n      \"pmids\": [\"32015510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cbl-mediated Syk degradation restrains plasma cell formation in germinal centers and promotes B cell light zone to dark zone transition. This degradation machinery attenuates BCR signaling by mitigating Kras/Erk and PI3K/Foxo1 pathways and restricting expression of plasma cell transcription factors in GC B cells.\",\n      \"method\": \"Mouse model defective in Cbl-mediated Syk degradation, signaling pathway analysis, transcription factor expression, flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model, multiple pathway readouts, single lab, mechanism linked to Cbl E3 ligase activity on Syk\",\n      \"pmids\": [\"31873727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Syk binds to nucleolin and phosphorylates it on tyrosine, enhancing nucleolin's ability to bind Bcl-xL mRNA and stabilize it, thereby protecting cells from apoptosis induced by oxidative or genotoxic stress.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, mRNA stability assay, RNA interference (nucleolin knockdown), apoptosis assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and phosphorylation demonstrated, functional RNAi knockdown with apoptosis readout, single lab\",\n      \"pmids\": [\"25092868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Syk is recruited to stress granules in a phosphorylation-dependent manner. Grb7 is a Syk-binding protein involved in recruiting Syk to stress granules. Syk recruitment promotes autophagosome formation and clearance of stress granules, enhancing cell survival after stress.\",\n      \"method\": \"Stress granule formation assay, Co-immunoprecipitation (Syk-Grb7), autophagosome formation assay, Syk inhibition/knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies Grb7 as recruitment factor, phosphorylation requirement established, functional autophagy readout, single lab\",\n      \"pmids\": [\"26429917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Conserved C-terminal tyrosines Tyr-623, Tyr-624, and Tyr-625 of Syk regulate its kinase activity and ITAM binding. Mutation of all three to Phe results in increased autophosphorylation in resting cells, reduced binding to phosphorylated ITAM, reduced kinase activity toward exogenous substrate, and decreased FcεRI-induced degranulation and downstream signaling. Tyr-624 and especially Tyr-625 have major roles.\",\n      \"method\": \"Site-directed mutagenesis, in vitro kinase assay, ITAM binding assay, degranulation assay, downstream signaling analysis in Syk-deficient mast cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific mutagenesis with in vitro kinase assay and functional reconstitution in deficient mast cells, multiple orthogonal methods\",\n      \"pmids\": [\"20554527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Syk is essential for γδTCR signal transduction and development of IL-17-producing γδT (γδT17) cells in the mouse thymus. Syk induces PI3K/Akt pathway activation upon γδTCR stimulation. ZAP70 cannot functionally substitute for Syk in γδT17 development. RhoH (adaptor that recruits Syk) deficiency ameliorates γδT17-dependent skin inflammation.\",\n      \"method\": \"Genetic mouse models (Syk conditional KO, RhoH KO, PI3K signaling-deficient mice), thymic development analysis, cytokine analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mouse models, pathway specificity (Syk vs ZAP70 non-substitutability), PI3K epistasis, in vivo inflammatory model\",\n      \"pmids\": [\"29202478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SYK-deficient microglia cannot encase Aβ plaques, accelerating brain pathology and behavioral deficits. SYK deficiency impairs the PI3K-AKT-GSK-3β-mTOR pathway, incapacitating anabolic support required for disease-associated microglia (DAM) profile. However, SYK-deficient microglia can still proliferate and advance to an Apoe-expressing prodromal DAM stage via the DAP10 adapter pathway. The human TREM2R47H variant associated with high AD risk fails to activate SYK.\",\n      \"method\": \"Conditional SYK knockout in microglia, 5xFAD mouse model, Aβ plaque encasement assay, PI3K-AKT pathway analysis, DAM transcriptional profiling, TREM2R47H knock-in mice\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo, pathway analysis, DAP10 vs SYK epistasis, human variant validation, multiple readouts\",\n      \"pmids\": [\"36306735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SYK inhibition blocks autophagic Tau degradation by acting upstream of the mTOR pathway. Pharmacological inhibition or knockdown of SYK decreases mTOR pathway activation and increases autophagic Tau degradation. In a tauopathy mouse model, chronic SYK inhibition reduced Tau accumulation, neuroinflammation, neuronal and synaptic loss, and reversed defective autophagy.\",\n      \"method\": \"SYK pharmacological inhibition, shRNA knockdown, mTOR pathway analysis, autophagic flux measurement, tauopathy mouse model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two loss-of-function approaches, mTOR pathway epistasis, in vivo validation, single lab\",\n      \"pmids\": [\"31324720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SYK inhibition decreases Aβ production and increases Aβ clearance across the blood-brain barrier. SYK inhibition induces increased phosphorylation of inhibitory Ser-9 of GSK-3β by activating protein kinase A, providing a mechanism for reduction of Tau phosphorylation at GSK3β-dependent epitopes.\",\n      \"method\": \"Pharmacological SYK inhibition, SYK siRNA knockdown, transgenic mouse models (Aβ overexpression, P301S Tau), BBB clearance assay, GSK-3β Ser-9 phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition, mechanistic link to PKA-GSK3β-Tau axis, in vivo mouse model, single lab\",\n      \"pmids\": [\"25331948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"When ZAP70 is aberrantly expressed in B cells, it competes with SYK at the BCR signalosome and redirects SYK from NFAT-dependent negative selection signaling to tonic PI3K signaling, promoting B cell survival and impairing elimination of autoreactive/premalignant clones.\",\n      \"method\": \"Conditional ZAP70 expression in B cells, genetic mouse models (B-ALL, B-CLL), BCR signaling pathway analysis (NFAT vs PI3K), negative selection assay, autoantibody measurement\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mouse models, pathway redirection mechanistically established (NFAT vs PI3K), autoimmune and malignancy phenotypes, single rigorous study\",\n      \"pmids\": [\"33878293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SYK regulates mTOR and its upstream activator AKT in AML. Both small-molecule SYK inhibition and SYK-directed shRNA suppressed mTOR and downstream signaling effectors, as well as AKT. SYK inhibition showed heterogeneous effects on MAPK pathway (downregulating MEK/ERK in some cell lines, paradoxical increase in RAS-mutated AML).\",\n      \"method\": \"Small-molecule SYK inhibition, shRNA knockdown, phospho-protein analysis (mTOR, AKT, MEK, ERK), AML cell viability assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two loss-of-function approaches (inhibitor + shRNA), multiple pathway readouts, single lab\",\n      \"pmids\": [\"23535559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CrkL binds to Syk through its SH2 and SH3 domains and co-precipitates kinase-active Syk. CrkL serves as a molecular adapter between WASP and Syk, with both SH2 and SH3 domains of CrkL involved in Syk binding. WASP, CrkL, Syk, and Hic-5 incorporate into platelet cytoskeleton after platelet aggregation.\",\n      \"method\": \"Co-immunoprecipitation, GST-fusion domain pulldown, in vitro kinase assay, platelet cytoskeleton fractionation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and in vitro kinase confirmation, single lab\",\n      \"pmids\": [\"11313252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Itaconate directly inhibits SYK kinase through alkylation at the Cys593 site, suppressing inflammation.\",\n      \"method\": \"Biochemical alkylation assay, SYK kinase activity assay, site-specific mutation (Cys593), pharmacological inhibition in macrophages and in vivo\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — site-specific alkylation identified, but single lab, limited mutagenesis detail in abstract\",\n      \"pmids\": [\"37897551\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SYK is a cytoplasmic non-receptor tyrosine kinase that is activated by binding of its tandem SH2 domains to dual-phosphorylated ITAMs in immune receptor signaling chains (BCR, FcRs, DAP12, CLEC-2) and by integrin β3 cytoplasmic tail binding in a phosphotyrosine-independent manner; full activation requires both ppITAM-mediated priming and LYN-mediated phosphorylation of the SH2-kinase linker (Tyr-348/352) followed by activation loop phosphorylation; once active, SYK phosphorylates key substrates (BLNK, PKCβI, α-tubulin, nucleolin, Btk) and signals through PI3K-AKT-mTOR, Ras/ERK, NF-κB, and NFAT pathways; its activity is spatiotemporally regulated by proteasomal degradation (Cbl), K27-linked polyubiquitination (TRIM31) promoting membrane translocation, deubiquitination (USP10), nucleocytoplasmic shuttling via a linker-domain sequence, and centrosomal localization; SYK is essential for B cell development, phagocytosis, NK cytotoxicity, γδT17 differentiation, platelet activation, microglial Aβ clearance, and vascular integrity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SYK is a cytoplasmic non-receptor tyrosine kinase that couples immunoreceptor and adhesion-receptor engagement to downstream activation of the actin cytoskeleton and the PI3K-AKT-mTOR, Ras/ERK, NF-\\u03baB, and NFAT signaling pathways [#0, #9, #14]. It is recruited to and activated by its tandem SH2 domains engaging dual-phosphorylated ITAMs in receptor signaling chains (e.g., the BCR Ig\\u03b1/\\u03b2 chains), with full activation requiring ppITAM-mediated priming followed by LYN-catalyzed phosphorylation of the SH2-kinase linker tyrosines Tyr-348/Tyr-352 and activation-loop phosphorylation [#0, #6]; it can also be engaged in a phosphotyrosine-independent manner through the integrin \\u03b23 cytoplasmic tail and through dimerization of single-YxxL receptors such as CLEC-2 [#1, #5]. Its clustered kinase domain is sufficient to autonomously drive phagocytosis and F-actin remodeling, and SYK directs actin dynamics, RhoA, and Vav during complement-mediated engulfment [#3, #7]. Active SYK propagates signaling by phosphorylating and partnering with substrates including the adaptor BLNK/SLP-65, which forms a positive-feedback complex and relays signal to Btk, PKC\\u03b2I to recruit Grb2/Sos for Ras/ERK activation, \\u03b1-tubulin, and nucleolin to stabilize Bcl-xL mRNA and resist apoptosis [#2, #4, #9, #10, #22]. SYK abundance and localization are tightly controlled by Cbl-mediated proteasomal degradation, TRIM31-catalyzed K27-linked polyubiquitination promoting membrane translocation, and USP10-mediated deubiquitinative stabilization [#19, #20, #21]. At the organismal level SYK is essential for B-cell development and vascular integrity, NK cytotoxicity, fungal/Dectin-1 immunity, \\u03b3\\u03b4T17 differentiation, and microglial encasement of amyloid plaques, and its dysregulation contributes to FLT3-ITD AML and to tau/A\\u03b2 pathology through mTOR and GSK-3\\u03b2 control [#0, #8, #14, #15, #25, #26, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that SYK is the obligate ITAM-coupled kinase linking immunoreceptors to lymphocyte development and that it is required for vascular integrity in vivo.\",\n      \"evidence\": \"Knockout mice plus biochemical ITAM-binding studies and pre-B cell development analysis\",\n      \"pmids\": [\"7477353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the activation-loop/linker phosphorylation steps required for catalytic activation\", \"Did not resolve which receptor partners account for the hemorrhagic phenotype\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed that the SYK kinase domain itself, when clustered, is sufficient to trigger phagocytosis and actin remodeling, defining a catalytic, kinase-dependent coupling to the cytoskeleton.\",\n      \"evidence\": \"Chimeric transmembrane SYK constructs with catalytic point mutant in COS cells, phagocytosis and actin assays\",\n      \"pmids\": [\"8577722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the cytoskeletal substrates downstream of the kinase domain\", \"Used a non-hematopoietic reconstitution system\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined non-canonical, phosphotyrosine-independent recruitment of SYK to the integrin \\u03b23 tail and identified direct receptor partners (EpoR) and adaptors (CrkL/WASP) that diversify SYK signaling beyond classical ITAMs.\",\n      \"evidence\": \"Co-IP, far-Western/SH2 domain mapping, deletion mutagenesis, adhesion and cytoskeletal fractionation assays\",\n      \"pmids\": [\"11719224\", \"9852052\", \"11313252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of phosphotyrosine-independent \\u03b23 binding not resolved\", \"Single-lab binding studies for several partners\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved how SYK transmits BCR signal to Btk, showing BLNK/SLP-65 acts as both substrate and bridging adaptor for Btk Tyr-551 phosphorylation.\",\n      \"evidence\": \"Reconstitution cell system plus BLNK- and SYK-deficient B cells\",\n      \"pmids\": [\"11226282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish stoichiometry of the SYK/BLNK/Btk assembly\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified a direct substrate-to-pathway link by which SYK phosphorylates PKC\\u03b2I/\\u03b1 to recruit Grb2/Sos and activate Ras/ERK in mast cells.\",\n      \"evidence\": \"In vitro kinase assay, phosphosite mutagenesis, SH2-binding and Ras/ERK readouts\",\n      \"pmids\": [\"12881490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dependence on prior PKC serine autophosphorylation leaves ordering of the kinase cascade incompletely mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated SYK requirement in complement (CR3)-mediated phagocytosis, linking it to RhoA and Vav-driven actin dynamics at the phagosome.\",\n      \"evidence\": \"siRNA and dominant-negative SYK, immunofluorescence, RhoA activation assays\",\n      \"pmids\": [\"16449524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the direct SYK substrate controlling actin depolymerization\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed SYK at the node integrating C-type lectin (Dectin-1) and TLR/MyD88 signals for optimal innate cytokine responses.\",\n      \"evidence\": \"SYK- and MyD88-deficient macrophages with cytokine and NF-\\u03baB readouts\",\n      \"pmids\": [\"18200499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular point of SYK\\u2013MyD88 pathway convergence not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a positive-feedback loop in which SLP-65 binds an autophosphorylated SYK tyrosine to amplify and sustain BCR-driven ERK/NF-\\u03baB/NFAT and Ca2+ signaling.\",\n      \"evidence\": \"Reciprocal Co-IP, mutant mice, calcium flux and pathway analysis\",\n      \"pmids\": [\"18369315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Akt arm shown to be SLP-65-independent but the alternate route not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Clarified activation mechanisms for non-ITAM receptors, showing CLEC-2 activates SYK via 2:1 cross-linking and that SYK can open BCR dimers by inside-out signaling to amplify receptor signaling.\",\n      \"evidence\": \"Biophysical stoichiometry (SPR, cross-linking, EM) and nanoscale proximity ligation assays\",\n      \"pmids\": [\"20154219\", \"24963139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inside-out conformational mechanism shown by a single method/lab\", \"How dimer cross-linking is regulated in vivo unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped intramolecular regulatory determinants, identifying C-terminal Tyr-623/624/625 that tune SYK kinase activity and ITAM binding.\",\n      \"evidence\": \"Site-directed mutagenesis with in vitro kinase, ITAM-binding, and degranulation assays in SYK-deficient mast cells\",\n      \"pmids\": [\"20554527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism by which these tyrosines couple to the active site not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Reconstituted the two-step activation logic of SYK: ppITAM priming enables rapid LYN-mediated linker phosphorylation (Tyr-352 then Tyr-348) and activation-loop phosphorylation for full activity.\",\n      \"evidence\": \"In vitro kinase assays with monomeric vs obligate-dimeric purified SYK plus phosphoproteomics\",\n      \"pmids\": [\"30923129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics of in-cell coordination between LYN and ITAM engagement not fully captured\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined ubiquitin-based control of SYK localization and stability: TRIM31 K27-linked polyubiquitination drives membrane translocation and CLR binding while blocking SHP-1, complementing Cbl-mediated degradation and USP10-mediated stabilization.\",\n      \"evidence\": \"Site-specific ubiquitination mutagenesis, membrane fractionation, TRIM31-/- mice; Cbl-degradation-defective mice; USP10 inhibitor studies\",\n      \"pmids\": [\"34362877\", \"31873727\", \"32015510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"USP10\\u2013SYK relationship inferred from inhibitor studies without direct DUB-substrate reconstitution\", \"Interplay between competing ubiquitin marks not integrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed SYK is non-redundantly required (ZAP70 cannot substitute) for \\u03b3\\u03b4TCR-driven PI3K/Akt signaling and \\u03b3\\u03b4T17 development.\",\n      \"evidence\": \"Conditional SYK, RhoH, and PI3K-mutant mice with thymic development and skin inflammation readouts\",\n      \"pmids\": [\"29202478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for SYK-vs-ZAP70 functional non-equivalence not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that aberrant ZAP70 competes with SYK at the BCR signalosome to redirect signaling from NFAT-driven negative selection to tonic PI3K survival signaling, promoting malignant/autoreactive clone persistence.\",\n      \"evidence\": \"Conditional ZAP70 expression and B-ALL/B-CLL mouse models with NFAT-vs-PI3K pathway analysis\",\n      \"pmids\": [\"33878293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical basis of differential pathway output between the two kinases not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined SYK as the signaling hub for disease-associated microglia, required for PI3K-AKT-GSK-3\\u03b2-mTOR anabolic support and A\\u03b2 plaque encasement, with the AD-risk TREM2 R47H variant failing to engage it.\",\n      \"evidence\": \"Microglial conditional SYK knockout in 5xFAD mice, DAM profiling, DAP10 epistasis, TREM2 R47H knock-in\",\n      \"pmids\": [\"36306735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SYK selectively enables DAM anabolic state vs DAP10-driven proliferation mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a small-molecule/metabolite control point: itaconate alkylates SYK Cys593 to inhibit its kinase activity and dampen inflammation.\",\n      \"evidence\": \"Biochemical alkylation, kinase activity assay, Cys593 mutation, in vivo macrophage inhibition\",\n      \"pmids\": [\"37897551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab with limited mutagenesis detail\", \"Structural consequence of Cys593 alkylation on the active site not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SYK's distinct signaling outputs (cytoskeletal, survival/mTOR, NF-\\u03baB/NFAT) are selected by receptor context, ubiquitin marks, and subcellular localization remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking activation mode to downstream pathway choice\", \"Functional consequences of centrosomal/nuclear SYK pools incompletely defined\", \"Structural basis of competing ubiquitin and phosphorylation marks unintegrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 3, 6, 9, 10, 22, 24]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 6, 9, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 9, 19]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 8, 14, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 14, 30]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [5, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [19, 20, 21]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [23, 27]}\n    ],\n    \"complexes\": [\"BCR signalosome\", \"platelet cytoskeleton (WASP/CrkL/Hic-5)\"],\n    \"partners\": [\"BLNK\", \"LYN\", \"Btk\", \"CLEC-2\", \"DAP12\", \"CrkL\", \"Grb7\", \"TRIM31\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}